Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant?

Abstract

To evaluate the statistical and clinical efficacy of the pharmacological treatments of nocturia using non-antidiuretic agents. A literature review of treatments of nocturia specifically addressing the impact of alpha blockers, 5-alpha reductase inhibitors (5ARI) and antimuscarinics on reduction in nocturnal voids. Despite commonly reported statistically significant results, nocturia has shown a poor clinical response to traditional therapies for benign prostatic hyperplasia including alpha blockers and 5ARI. Similarly, nocturia has shown a poor clinical response to traditional therapies for overactive bladder including antimuscarinics. Statistical success has been achieved in some groups with a variety of alpha blockers and antimuscarinic agents, but the clinical significance of these changes is doubtful. It is likely that other types of therapy will need to be employed in order to achieve a clinically significant reduction in nocturia.

• Authors: Ariana L Smith, Alan J Wein
• Journal: BJU international (BJU Int) Vol. 107 Issue 10 Pg. 1550-4 (May 2011) ISSN: 1464-410X [Electronic] England
• PMID: 21518417 (Publication Type: Journal Article, Review)
• Copyright: © 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Chemical References

• 5-alpha Reductase Inhibitors
• Adrenergic alpha-Antagonists
• Muscarinic Antagonists

Topics

• 5-alpha Reductase Inhibitors (therapeutic use)
• Adrenergic alpha-Antagonists (therapeutic use)
• Aged
• Drug Therapy, Combination
• Epidemiologic Methods
• Female
• Humans
• Male
• Middle Aged
• Muscarinic Antagonists (therapeutic use)
• Nocturia (complications, drug therapy)
• Prostatic Hyperplasia (complications, drug therapy)
• Treatment Outcome
• Urinary Bladder, Overactive (complications, drug therapy)